Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection

Hepatology Research

Volumn 48, Issue 7, 2018, Pages 566-573

  Miquelestorena Standley, Elodie ^a,b,c   Tallet, Anne ^a,b,c   Collin, Christine ^a   Piver, Eric ^a,b,c   De Muret, Anne ^a   Salamé, Ephrem ^a,b   Bourlier, Pascal ^a   Kervarrec, Thibault ^a,b   Guyétant, Serge ^a,b   Pagès, Jean Christophe ^a,b,c  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c INSERM   (France)

Author keywords

HCV; hepatitis C virus; hepatocellular carcinoma; miR 122; miR 152

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 152; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER TISSUE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; LIVER TISSUE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CARCINOGENESIS;

EID: 85021452212     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12915     Document Type: Article

References (34)

1. Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon 2012; 12: e6894.
2. Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837–849.
3. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012; 12(Suppl 2): S2.
4. Fung J, Lai C-L, Yuen M-F. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect Dis 2009; 15: 964–970.
5. Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J 2014; 11: 64.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866.
7. Chen Y, Song Y-X, Wang Z-N. The microRNA-148/152 family: multi-faceted players. Mol Cancer 2013; 12: 43.
8. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9: 287–314.
9. Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 2014; 346: 17–23.
10. Volinia S, Calin GA, Liu C-G et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257–2261.
11. Zhu C, Li J, Ding Q et al. MiR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines. Prostate 2013; 73: 1082–1089.
12. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52: 60–70.
13. Tsuruta T, Kozaki K-I, Uesugi A et al. MiR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71: 6450–6462.
14. Dang Y-W, Zeng J, He R-Q, Rong M-H, Luo D-Z, Chen G. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev 2014; 15: 4969–4976.
15. Hou J, Lin L, Zhou W et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232–243.
16. Spaniel C, Honda M, Selitsky SR et al. MicroRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from japanese patients with persistent HCV versus HBV infection. PLoS One 2013; 8: e76867.
17. Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013; 19: 7836–7845.
18. Varnholt H, Drebber U, Schulze F et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223–1232.
19. Trebicka J, Anadol E, Elfimova N et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58: 234–239.
20. El-Garem H, Ammer A, Shehab H et al. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014; 6: 818–824.
21. Wang F, Ying H, He B, Pan Y, Sun H, Wang S. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma. Tumour Biol 2016; 37: 4945–4953.
22. Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092–6099.
23. Boštjančič E, Bandelj E, Luzar B, Poljak M, Glavač D. Hepatic expression of miR-122, miR-126, miR-136 and miR-181a and their correlation to histopathological and clinical characteristics of patients with hepatitis C. J Viral Hepat 2015; 22: 146–157.
24. Song K, Han C, Zhang J et al. Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptor-γ and hepatitis B virus X protein in hepatocellular carcinoma cells. Hepatology 2013; 58: 1681–1692.
25. Thibault PA, Huys A, Dhillon P, Wilson JA. MicroRNA-122-dependent and -independent replication of hepatitis C virus in Hep3B human hepatoma cells. Virology 2013; 436: 179–190.
26. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. MiR-122 – a key factor and therapeutic target in liver disease. J Hepatol 2015; 62: 448–457.
27. Jiang J, Gusev Y, Aderca I et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419–427.
28. Yuan K, Lian Z, Sun B, Clayton MM, Ng IOL, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One 2012; 7: e35331.
29. Huang S, Xie Y, Yang P, Chen P, Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS One 2014; 9: e81730.
30. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526–3536.
31. Fiorino S, Bacchi-Reggiani ML, Visani M et al. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol 2016; 22: 3907–3936.
32. Lamba V, Ghodke-Puranik Y, Guan W, Lamba JK. Identification of suitable reference genes for hepatic microRNA quantitation. BMC Res Notes 2014; 7: 129.
33. Li X, Yang W, Ye W, Jin L, He J, Lou L. MicroRNAs: novel players in hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2014; 38: 664–675.
34. Coenen-Stass AM, Betts CA, Lee YF et al. Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation. Hum Mol Genet 2016; 25: 3960–3974.